EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Parkinson disease therapy: current strategies and future research priorities

Fabrizio Stocchi iD, Daniele Bravi, Aron Emmi iD, Angelo Antonini

Nature Reviews Neurology · 2024-12 · 20 (12) · 695-707

DOI: 10.1038/s41582-024-01034-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nature Reviews Neurology, online erschienen am 04.11.2024. Verfasst von Fabrizio Stocchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University San Raffaele, Rome, Italy. fabrizio.stocchi@sanraffaele.it. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 230-mal zitiert (Crossref) und nennt 138 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson disease (PD) is the fastest growing neurological disorder globally and poses substantial management challenges owing to progressive disability, emergence of levodopa-resistant symptoms, and treatment-related complications. In this Review, we examine the current state of research into PD therapies and outline future priorities for advancing our understanding and treatment of the disease. We identify two main research priorities for the coming years: first, slowing the progression of the disease through the integration of sensitive biomarkers and targeted biological therapies, and second, enhancing existing symptomatic treatments, encompassing surgical and infusion therapies, with the goal of postponing complications and improving long-term patient management. The path towards disease modification is impeded by the multifaceted pathophysiology and diverse mechanisms underlying PD. Ongoing studies are directed at α-synuclein aggregation, complemented by efforts to address specific pathways associated with the less common genetic forms of the disease. The success of these efforts relies on establishing robust end points, incorporating technology, and identifying reliable biomarkers for early diagnosis and continuous monitoring of disease progression. In the context of symptomatic treatment, the focus should shift towards refining existing approaches and fostering the development of novel therapeutic strategies that target levodopa-resistant symptoms and clinical manifestations that substantially impair quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansAntiparkinson AgentsBiomedical ResearchDisease ProgressionBiomarkers

Substanzen

Antiparkinson AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, University San Raffaele, Rome, Italy. fabrizio.stocchi@sanraffaele.it.
  • Deptartment of Neurology, Institute for Research and Medical Care, IRCCS San Raffaele, Rome, Italy. fabrizio.stocchi@sanraffaele.it.
  • Deptartment of Neurology, Institute for Research and Medical Care, IRCCS San Raffaele, Rome, Italy.
  • Center for Neurodegenerative Diseases (CESNE), Department of Neuroscience, University of Padova, Padova, Italy.
  • Institute of Human Anatomy, Department of Neuroscience, University of Padova, Padova, Italy.
  • Parkinson and Movement Disorders Unit, Centre for Rare Neurological Diseases (ERN-RND), Department of Neuroscience, Padua Neuroscience Center (PNC), University of Padova, Padova, Italy.

ORCID-Profile: Fabrizio Stocchi, Aron Emmi

Zitieren

APA

Stocchi, F., Bravi, D., Emmi, A., & Antonini, A. (2024). Parkinson disease therapy: current strategies and future research priorities. Nature Reviews Neurology, 20(12), 695-707. https://doi.org/10.1038/s41582-024-01034-x

Vancouver

Stocchi F, Bravi D, Emmi A, Antonini A. Parkinson disease therapy: current strategies and future research priorities. Nature Reviews Neurology. 2024;20(12):695-707. doi:10.1038/s41582-024-01034-x

BibTeX
@article{Stocchi2024,
  author = {Stocchi, Fabrizio and Bravi, Daniele and Emmi, Aron and Antonini, Angelo},
  title = {Parkinson disease therapy: current strategies and future research priorities},
  journal = {Nature Reviews Neurology},
  year = {2024},
  volume = {20},
  number = {12},
  pages = {695--707},
  doi = {10.1038/s41582-024-01034-x}
}
Kostenlos starten →